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Abstract
Background: Various biomarkers for prediction of distant metastasis in lymph-node negative breast cancer have been 
described; however, predictive biomarkers for patients with lymph-node positive (LNP) disease in the context of 
distinct systemic therapies are still very much needed. DNA methylation is aberrant in breast cancer and is likely to play 
a major role in disease progression. In this study, the DNA methylation status of 202 candidate loci was screened to 
identify those loci that may predict outcome in LNP/estrogen receptor-positive (ER+) breast cancer patients with 
adjuvant anthracycline-based chemotherapy.
Methods: Quantitative bisulfite sequencing was used to analyze DNA methylation biomarker candidates in a 
retrospective cohort of 162 LNP/ER+ breast cancer patients, who received adjuvant anthracycline-based 
chemotherapy. First, twelve breast cancer specimens were analyzed for all 202 candidate loci to exclude genes that 
showed no differential methylation. To identify genes that predict distant metastasis, the remaining loci were analyzed 
in 84 selected cases, including the 12 initial ones. Significant loci were analyzed in the remaining 78 independent cases. 
Metastasis-free survival analysis was conducted by using Cox regression, time-dependent ROC analysis, and the 
Kaplan-Meier method. Pairwise multivariate regression analysis was performed by linear Cox Proportional Hazard 
models, testing the association between methylation scores and clinical parameters with respect to metastasis-free 
survival.
Results: Of the 202 loci analysed, 37 showed some indication of differential DNA methylation among the initial 12 
patient samples tested. Of those, 6 loci were associated with outcome in the initial cohort (n = 84, log rank test, p < 
0.05).
Promoter DNA methylation of cysteine dioxygenase 1 (CDO1) was confirmed in univariate and in pairwise multivariate 
analysis adjusting for age at surgery, pathological T stage, progesterone receptor status, grade, and endocrine therapy 
as a strong and independent biomarker for outcome prediction in the independent validation set (log rank test p-value 
= 0.0010).
Conclusions: CDO1 methylation was shown to be a strong predictor for distant metastasis in retrospective cohorts of 
LNP/ER+ breast cancer patients, who had received adjuvant anthracycline-based chemotherapy.
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Breast cancer is the most frequent cancer in women (27%
of all cancers, United States 2009), accounting for 15% of
all female cancer deaths [1]. Chemotherapy of breast can-
cer has progressed substantially over the past decades.
Anthracyclines, introduced in the 1980s, are among the
most potent agents for treatment of breast cancer and
thus are components of many (neo)-adjuvant and pallia-
tive regimens, more recently often in combination with
taxanes [2].
In node-positive breast cancer, anthracycline-based
adjuvant chemotherapy has become the standard of care
since the 1990s [3]; 69% of LNP breast cancer patients
remained disease-free after five years after treatment with
anthracycline-based chemotherapy [4]. Those long-term
disease-free patients are supposed to have been effectively
treated and any more aggressive treatment thus seems to
be unnecessary. Yet, treatment with anthracyclines is
linked with both, acute and long-term side effects, most
notably cardiotoxicity [8]. Therefore, if a biomarker was
available to reliably identify LNP patients with a low risk of
recurrence after adjuvant anthracycline-based chemother-
apy, further treatment of this patient group with other che-
motherapy agents could be avoided. Biomarkers,
specifically predictive for the outcome of patients treated
with anthracyclines alone, are therefore essential and will
help personalize decisions regarding whether to incorpo-
rate additional chemotherapy agents into adjuvant therapy
regimens for individual patients.
DNA methylation plays an important role in funda-
mental biological processes such as development and cel-
lular differentiation [9]. DNA methylation has been
shown to play a major role in carcinogenesis and cancer
progression [10], suggesting that DNA methylation analy-
sis may be a valuable source of predictive and/or prog-
nostic biomarkers [11]. In this study, quantitative bisulfite
sequencing [12] was used to screen 202 biomarker candi-
dates for their prognostic impact in LNP/ER+ breast can-
cer patients who had received adjuvant anthracycline-
based chemotherapy. The marker candidates were
selected from the literature or identified by differential
methylation hybridization (DMH) technology, a method
for genome-wide discovery of methylation biomarkers
[13]. Promoter DNA methylation of cysteine dioxygenase
1 (CDO1) was identified as a strong predictor of distant
metastasis. This finding was confirmed in an indepen-
dent patient group of advanced LNP/ER+ breast cancer
patients treated with adjuvant anthracycline-based che-
motherapy.
Methods
Patients
The study cohort was comprised of 162 breast cancer
patients whose tumor samples were obtained from 4 clin-
ical centers: Erasmus Medical Center, Rotterdam, The
Netherlands; Centre René Huguenin, St. Cloud, France;
Stiftung Tumorbank Basel, Basel, Switzerland; and
Department of Obstetrics and Gynecology, Technical
University of Munich, Germany. Appropriate consent,
according to institutional requirements, was obtained
from all patients. The study protocol was approved by the
local ethics committees. Patient characteristics are shown
in Table 1. All breast cancer patients were anthracycline-
treated with estrogen receptor-positive, lymph node-pos-
itive tumors.
DNA Preparation
Leftover bisulfite DNA was used, which was prepared in
the course of a previous study [14]. In brief, snap-frozen
tumor tissue or tumor cell nuclei pelleted at 100,000 g
were used to obtain genomic DNA as previously
described [15]. Genomic DNA was extracted using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany), fol-
lowing the manufacturer's instructions (tissue protocol).
The DNA concentration was quantified by UV spectro-
photometry using a Nanodrop® ND-1000 spectral pho-
tometer (Nanodrop Technologies, DE, USA). Artificially
methylated DNA (CpGenome™ Universal Methylated
DNA, Millipore, MA, USA) was used as completely
methylated reference DNA. Two μg of extracted DNA
was bisulfite converted using the EpiTect® Kit (Qiagen,
Hilden, Germany) according to the manufacturer's rec-
ommendations with the exception that no carrier RNA
was used. DNA concentration was quantified via UV
spectrophotometry as described above.
PCR Amplification
PCR amplification was done in a 25 μl volume (1 U Hot-
Star Taq polymerase [Qiagen, Hilden, Germany], 1 × PCR
buffer [Qiagen, Hilden, Germany], 0.2 mM each dNTP
[Fermentas, Burlington, Canada], 0.5 μM both primers
[MWG-Biotech, Ebersberg, Germany], and 20 ng tem-
plate DNA). Incubation was done using the following
temperature profile: 15 min/95°C and 45 cycles with 20 s/
95°C, 45 s/58°C and 30 s/72°C. The primer sequences and
the sequences of the respective target loci (prior to
bisulfite conversion) are listed in the Additional file 1:
Analyzed genes and primer sequences. Each reverse
primer contained the sequence CGTCGTCG at its 5' end.
Sequencing and Raw Data Processing
Quantitative bisulfite sequencing was carried out as pre-
viously described [12]. ABI sequencing electrophero-
grams were converted to text files using BioEdit 6.0.7
software and imported into Microsoft Excel. The trace
containing the methylation information was visualized
and the normalization signal identified. The electro-
pherograms were shifted until the normalization signal of
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Table 1: Characteristics of the 162 estrogen receptor-positive and lymph node positive breast cancer patients treated with 
anthracyclines.
Training Set† Validation Set
All Distant Metastasis All Distant Metastasis
Total Number of Patients 84 (100%) 39 78 (100%) 25
Follow-up
Median follow-up [Months] 80 53.5
Range [Months] 6-144 5-166
Age at Diagnosis
≤ 50 Years 38 (45%) 20 41 (53%) 16
> 50 Years 46 (55%) 19 37 (47%) 19
Median Age (Years) 49 49
Range (Years) 29-71 33 - 81
T stage
≤ 2 cm (T1) 19 (23%) 4 24 (31%) 5
> 2 cm (T2+T3) 63 (75%) 35 53 (68%) 19
Unknown 2 (2%) 0 1 (1%) 1
Tumor Grade
G1 2 (2%) 0 3 (4%) 1
G2 24 (29%) 11 30 (38%) 7
G3 47 (56%) 21 28 (36%) 11
Unknown 11 (13%) 7 17 (22%) 6
Estrogen Receptor Status
Negative 0 0 0 0
Positive 84 (100%) 39 78 (100%) 25
Progesterone Receptor Status
Negative 12 (14%) 4 18 (23%) 9
Positive 72 (86%) 35 60 (77%) 16
Endocrine Treatment
Yes 22 (26%) 8 37 (47%) 9
No 61 (73%) 30 40 (51%) 15
Unknown 1 (1%) 1 1 (1%) 1
†The training set was enriched for specimens that lack PITX2 methylation.
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malization signal was integrated and each data point of
the electropherogram divided by this normalization
value. The analyzed PCR fragments contained several
CpG sites. The signals of the single CpG sites of com-
pletely methylated DNA were used to identify the CpG
positions in the electropherograms of the patient sam-
ples. The maximum intensity of a specific CpG site was
defined as the maximum in the region ± 30 data points
referred to the respective peak in the reference trace of
the completely methylated DNA. The averaged intensi-
ties of all CpG sites from one PCR fragment were used as
measurement (methylation score) for statistical analysis.
Statistical Analysis
Time-dependent ROC curves for censored survival data
and the resulting AUC were calculated according to Hea-
gerty et al. [16]. WinSTAT for Microsoft Excel http://
www.winstat.com was used for Kaplan-Meier survival
analysis and log rank test. The median methylation value
in the respective patient group was used as the cut point
for dichotomization.
The relation between time to distant metastasis and
DNA methylation score was analyzed by a linear univari-
ate Cox Proportional Hazard model. Likelihood ratio
tests were performed to test for a significant impact of
DNA methylation score for the CDO1 amplificate on
clinical end points. Hazard Ratios for continuous vari-
ables were calculated. Pairwise multivariate regression
analysis, testing the association between clinical end
point and DNA methylation score and/or clinical param-
eters, was performed by employing linear Cox Propor-
tional Hazard models.
Results
A recently published novel method for quantitative
bisulfite sequencing [12] was used to analyze the methy-
lation status of 202 potential DNA methylation biomark-
ers in tumors from 162 anthracycline-treated, estrogen
receptor-positive, lymph node-positive breast cancer
patients in order to evaluate their potential to predict dis-
tant metastasis. Information about all analyzed genes can
be found in the Additional file 1: Analyzed genes and
primer sequences. The marker candidates were taken
from the literature or have previously been identified
using differential methylation hybridization (DMH), a
genome-wide discovery method (data not shown). A con-
secutive marker selection procedure as depicted in Figure
1 was developed in order to efficiently identify DNA
methylation biomarkers for outcome prediction. In a first
selection step, all 202 loci were analyzed using bisulfite
treated DNA from 12 randomly selected individual
tumors to exclude those that showed no evidence of dif-
ferential methylation among the samples. The remaining
candidates were further tested for their potential ability
to predict distant metastasis in a set of 72 additional
patient specimens, resulting in a training group of 84
patients in total. In the final step of analysis, the signifi-
cant DNA methylation biomarkers evolving from the
training set were further analyzed in an independent vali-
dation set of DNA samples from 78 patients, in order to
confirm and validate their true clinical potential. The
characteristics of patients belonging to the training and
validation sets are shown in Table 1.
From the initially analyzed 202 loci, 165 did not show
an apparent differential DNA methylation pattern among
the initial 12 samples tested, and therefore these loci were
excluded from further analyses. Of the remaining 37 can-
didates, six loci were associated with the occurrence of
distant metastasis in this training population. The methy-
lation data of these 37 candidates and the clinical infor-
mation of the 162 patients are shown in the Additional
file 2. Time-dependent ROC analysis and Kaplan-Meier
analysis was performed. In order to avoid an overly opti-
mistic result, the median DNA methylation score of the
training set was used as the cut point. The results of the
DNA methylation biomarkers containing prognostic
information in the training set are shown in Table 2. Six
genes (CDO1, APC, ZBTB16, NCR1, POU4F3, and
CXCL12) emerged as potential biomarkers in the training
set indicated by p < 0.05 and AUC > 0.6. Analysis of the
Figure 1 Overview of the marker candidate selection procedure 
(description in text).
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ability of the CDO1 gene to predict outcome (p = 0.0010,
AUC = 0.69) while the predictive ability of DNA methyla-
tion of the other five genes could not be confirmed in the
validation set, although ZBTB16 and POU4F3 just failed
statistical significance. The result for CDO1 still
remained significant after a Bonferroni correction for 6
tests (p = 0.0060). The Kaplan-Meier survival plots strati-
fied by the DNA methylation status of CDO1 both in the
training and validation set are depicted in Figure 2. Evi-
dently, DNA methylation of CDO1 is a strong biomarker
to predict distant metastasis in LNP patients with ER+
tumors treated with adjuvant anthracycline containing
therapy. Table 3 shows the results of the univariate and
the pairwise multivariate Cox Proportional Hazard mod-
els of the validation population (n = 78). In univariate
analysis, the DNA methylation score for CDO1 is associ-
ated with a high risk of distant recurrence in this patient
group (p = 0.0098, HR = 3.7, 95% CI 1.4 - 9.8). In addition,
progesterone receptor status (p = 0.0190, HR = 2.7, 95%
CI 1.2 - 6.0) was significantly associated with time-to-dis-
tant metastasis in this group whereas tumor stage, endo-
crine treatment, tumor grade, and age at surgery were
not. CDO1 DNA methylation was a significant marker in
the pairwise multivariate analysis including age at sur-
gery, pathological T stage, progesterone receptor status,
tumor grade or endocrine therapy. Patients who suffered
disease recurrence showed higher DNA methylation of
the CDO1 locus than those surviving metastasis-free.
A subset of the patient samples (n = 136) were also
included in a previous microarray study, where DNA
methylation of BMP4, FGF4, and C20orf55 was identified
as biomarkers for outcome prediction [14]. The p-values
obtained by the log rank test in Kaplan-Meier survival
analysis revealed comparable clinical performance of the
CDO1 methylation biomarker in this subgroup as com-
pared to FGF4 (CDO1 p = 0.0017, FGF4 p = 0.0030).
BMP4 and C20orf55 were not significant in this small
subgroup of patients (C20orf55 p = 0.4948, BMP4 p =
0.1100). The median DNA methylation score from the
136 patient samples was used as the cut point for patient
stratification.
Discussion
DNA methylation of 202 loci was analyzed in tumors
from breast cancer patients who were estrogen receptor-
positive, lymph node-positive, and treated with adjuvant
anthracycline-based chemotherapy, in order to identify
biomarkers to predict patient outcome. Patient samples
from this study were previously used to identify a four-
marker panel including PITX2, BMP4, FGF4, and
C20orf55 which enabled outcome prediction in lymph
node-positive, HER-2-negative breast cancer patients
treated with anthracycline-based chemotherapy [14].
In the presented study, cysteine dioxygenase 1 (CDO1)
was identified as a strong DNA methylation biomarker
for outcome prediction in the analyzed patient group.
CDO1 was previously discovered as a candidate bio-
marker using the DMH method by determining its DNA
methylation status in tumors from patients with meta-
static breast cancer who were treated by FAC (5-fluorou-
racil, adriamycine, and cyclophosphamide) regimen as
first-line therapy. The CDO1 gene encodes for an enzyme
that converts cysteine to cysteine sulphinic acid and is the
rate-limiting step in sulphate production. CDO1 is
understood to be one of the key enzymes in the taurine
Table 2: Time-dependent ROC analysis of the candidate genes in the training and validation set of LNP patients with ER+ 
tumors treated with adjuvant anthracycline containing therapy.
Training Set (n = 84) Validation Set (n = 78)
Gene AUC† p-value‡ AUC† p-value‡
CDO1 0.70 0.0034 0.69 0.0010
APC 0.68 0.0204 0.55 0.5306
ZBTB16 0.67 0.0224 0.63 0.0582
NCR1 0.63 0.0239 0.56 0.9048
POU4F3 0.69 0.0248 0.69 0.0754
CXCL12 0.67 0.0282 0.49 0.4854
†Shown are the AUC of the ROC at 48 months after surgery
‡ The p-values are those obtained by the log rank test in Kaplan-Meier survival analysis and the genes are ranked according these p-values. 
The median DNA methylation score from the training set and the validation set, respectively, was used as the cut point.
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21]. The human CDO1 gene is located at chromosome
5q23.2 and is homologous to the rat and murine cysteine
dioxigenases. Murine Cdo1 may be involved in the regu-
lation of protein function and antioxidant defense mecha-
nisms through its ability to oxidize cysteine residues [22].
Staub et al. [23] assumed that deletion or epigenetic
silencing of the chromosomal region where CDO1 is
located is a frequent mechanism contributing to colorec-
tal tumorigenesis. Recently, over-expression of CDO1
Table 3: Univariate and pairwise multivariate Cox Proportional Hazards analysis for time-to-distant metastasis.
Number of samples Hazard Ratio (95% CI) p-value‡
Univariate Analysis†
CDO1 DNA Methylation 78 3.7 (1.4 - 9.8) 0.0098
Age at Surgery 78 1.3 (0.6 - 2.8) 0.5545
Tumor Stage (T2,T3 vs. T1) 78 2.0 (0.7 - 5.2) 0.1799
Progesterone Receptor Status
(Positive vs. Negative)
77 2.7 (1.2 - 6.0) 0.0190
Endocrine Treatment
(No vs. Yes)
77 2.0 (0.9 - 4.5) 0.1115
Tumor Grade (3 vs.1,2) 61 2.0 (0.8 - 4.9) 0.1397
Pairwise Multivariate Analysis†
CDO1 DNA Methylation 78 3.9 (1.5 - 10.5) 0.0072
Age at Surgery 78 1.5 (0.7 - 3.4) 0.3160
CDO1 DNA Methylation 77 3.5 (1.3 - 9.5) 0.0128
T Stage (T2,T3 vs. T1) 77 2.0 (0.7 - 5.3) 0.1790
CDO1 DNA Methylation 78 3.5 (1.3 - 9.4) 0.0123
Progesterone Receptor Status
(Positive vs. Negative)
78 2.5 (1.1 - 5.7) 0.0275
CDO1 DNA Methylation 77 4.6 (1.6 - 13.5) 0.0055
Endocrine Treatment
(No vs. Yes)
77 2.0 (0.9 - 4.7) 0.0938
CDO1 DNA Methylation 61 3.1 (1.1 - 8.7) 0.0318
Tumor Grade (3 vs.1,2) 61 1.7 (0.7 - 4.3) 0.2506
†CDO1 DNA methylation and age at surgery were analyzed as continuous variables. T stage, endocrine treatment and progesterone receptor 
status were analyzed as binary variables.
‡p-values refer to Likelihood-ratio test.
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cutaneous T-cell lymphoma [24].
Nonetheless, as of today, no aberrant DNA methylation
of the CDO1 gene has been described in the context of
breast cancer. Expression of cysteine dioxygenase was
found in ductal cells of pregnant rats, but not in other
mammary epithelial cells or in ductal cells of nonpreg-
nant rats [25]. Interestingly, repression of Cdo1 expres-
sion was identified to be associated with the malignant
transition from mammary intraepithelial neoplasia to
tumors in an engineered mouse-based model of ductal
carcinoma in situ [26]. However, whether the observed
repression was caused by DNA methylation of CDO1 was
not assessed in that study.
The results of this study do not show if methylation of
CDO1 is a general prognostic biomarker which is inde-
pendent of the nature of the adjuvant treatment or if it is
predictive for a response to an adjuvant anthracycline-
based chemotherapy. Further studies with other patient
populations such as patients who did not receive an adju-
vant anthracycline-based chemotherapy or the functional
analysis of cell lines might shed further light on a poten-
tial predictive value of CDO1 methylation.
Conclusions
DNA methylation of CDO1 was found to be a strong bio-
marker for prediction of distant recurrence in lymph
node-positive patients with estrogen receptor-positive
tumors treated with adjuvant anthracycline containing
therapy.
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Figure 2 Kaplan-Meier analysis of metastasis-free survival in the training (84 patients) and the validation set (78 patients) of lymph node-
positive patients with estrogen receptor-positive tumors treated with adjuvant anthracycline containing therapy and stratified by the 
DNA methylation status of CDO1. Median methylation of the respective population was used as the cut point
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